Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 24, 2024Research Journal of Pharmacy and Technology

Quantification of Asciminib and its impurities: A RP-UPLC study

View Full Paper
Ask AI
Bookmark
Share

Authors

SPS PallaviSGSowjanya GummadiGITAM University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pallavi et al. (2024) studied this question.

synapsesocial.com/papers/68e5f50bb6db64358758974chttps://doi.org/10.52711/0974-360x.2024.00537
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL12018 · 469 citations
  2. 2A Novel Stability Indicating Reversed Phase Ultra Performance Liquid Chromatography Method for Estimation of Asciminib its Bulk and Tablet Formulation2022 · 5 citations
  3. 3A Novel Method Development and Validation by Ultra-Performance Liquid Chromatography for Assay of Asciminib in Dosage Form2023 · 6 citations
  4. 4Bio-Analytical Method Development and Validation of Asciminib and its Application to Pharmacokinetic Studies in Rat Plasma by Using RP-HPLC2023 · 6 citations
  5. 5Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects2019 · 30 citations